Related Experiment Video
Updated: Apr 23, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
Published on: July 17, 2019
TWIK-2 channel deficiency leads to pulmonary hypertension through a rho-kinase-mediated process
Lavannya M Pandit1, Eric E Lloyd2, Julia O Reynolds2
1From the Departments of Internal Medicine (L.M.P., X.H.T.W., R.M.B.), Anesthesiology (E.E.L., R.M.B.), Cardiovascular Research Institute, Department of Molecular Physiology and Biophysics (J.O.R., C.R., X.H.T.W., R.M.B.), Baylor College of Medicine, and Department of Microbiology and Immunology (W.S.L.), The University of Texas Medical Branch lpandit@bcm.edu.
Abstract:
TWIK-2 (KCNK6) is a member of the 2-pore domain (K2P) family of potassium channels, which are highly expressed in the vascular system. We tested the hypothesis that TWIK-2 deficiency leads to pulmonary hypertension. TWIK-2 knockout mice and their wildtype littermates at 8 weeks of age had similar mean right ventricular systolic pressures (24±3 and 21±3 mm Hg, respectively.) Significantly, by 20 weeks of age, the mean right ventricular systolic pressures in TWIK-2 knockout mice increased to 35±3 mm Hg (P≤0.036), whereas mean right ventricular systolic pressures in wildtype littermates remained at 22±3 mm Hg. Elevated mean right ventricular systolic pressures in the TWIK-2 knockout mice was accompanied by pulmonary vascular remodeling as determined by a 25% increase in the cross-sectional area of the vessels occupied by the vessel wall. Additionally, secondary branches of the pulmonary artery from 20-week-old TWIK-2 knockout mice showed an enhanced contractile response to U46619 (10(-6) moles/L), a thromboxane A2 mimetic, which was completely abolished with the Rho-kinase inhibitor, Y27632 (10(-6) and 10(-5) moles/L). Treatment of TWIK-2 knockout mice with the Rho-kinase inhibitor, fasudil, in the drinking water for 12 weeks, abolished the development of pulmonary hypertension and attenuated the vessel remodeling. We concluded that mice deficient in the TWIK-2 channel develop pulmonary hypertension between 8 and 20 weeks of age through a mechanism involving Rho-kinase. Our results suggest that downregulation of TWIK-2 in the pulmonary vasculature may be an underlying mechanism in the development of pulmonary hypertension.
Insights
TWIK-2 channel deficiency causes pulmonary hypertension in mice by 20 weeks of age. This condition involves vascular remodeling and Rho-kinase activation, suggesting TWIK-2
Area of Science:
- Cardiovascular Biology
- Ion Channel Physiology
- Pulmonary Hypertension Research
Background:
- TWIK-2 (KCNK6) is a 2-pore domain potassium channel highly expressed in the vascular system.
- Pulmonary hypertension is a serious condition characterized by high blood pressure in the pulmonary arteries.
Purpose of the Study:
- To investigate the role of TWIK-2 in the development of pulmonary hypertension.
- To determine if TWIK-2 deficiency leads to pulmonary vascular remodeling and altered vascular contractility.
Main Methods:
- Utilized TWIK-2 knockout mice and wildtype littermates for comparative studies.
- Measured mean right ventricular systolic pressures and assessed pulmonary vascular remodeling.
- Evaluated pulmonary artery contractility and the effects of Rho-kinase inhibitors.
Main Results:
- TWIK-2 knockout mice developed significantly elevated right ventricular systolic pressures by 20 weeks of age compared to wildtype.
- Pulmonary hypertension in knockout mice was associated with increased vessel wall area and enhanced contractile responses.
- Inhibition of Rho-kinase activity with Y27632 or fasudil ameliorated hypertension and vascular remodeling.
Conclusions:
- TWIK-2 deficiency leads to the development of pulmonary hypertension between 8 and 20 weeks of age in mice.
- The mechanism involves Rho-kinase activation and pulmonary vascular remodeling.
- Downregulation of TWIK-2 may be a contributing factor to pulmonary hypertension pathogenesis.
Related Concept Videos
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Receptor Tyrosine Kinases
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
PI3K/mTOR/AKT Signaling Pathway
Regulation of Angiogenesis and Blood Supply
The JAK-STAT Signaling Pathway

